Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

is of safety and efficacy to be conducted based on predefined criteria. Kosan anticipates providing more information on the TIME-1 trial design upon initiation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is designed to enroll approximately 130 patients with relapsed-refractory multiple myeloma. The trial is designed to test three different doses of tanespimycin in combination with the approved dose and schedule of bortezomib (Velcade(R)) (1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and 340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour intravenous infusion on a cycle of two weeks of treatment every three weeks (the same schedule as bortezomib). Patients eligible to participate in the TIME-2 trial must have been treated with and progressed following at least three prior treatments for multiple myeloma. Prior regimens must include bortezomib and lenalidomide (Revlimid(R)). The primary endpoint of the trial is the dose response based on objective response rate after 4 cycles of treatment. Secondary endpoints include a comparison of response rate between the three dose groups, progression-free survival, time to treatment failure and overall survival. Objective response rate in multiple myeloma is measured primarily by the patient's level of M protein.

About the Special Protocol Assessment

As stated in the Prescription Drug User Fee Act (PDUFA) and FDA's Guidance for Industry Special Protocol Assessment, "...having agreed to the design, execution, and analyses proposed in protocols reviewed under this process ... the Agency will not later alter its perspective on the issues of design, execution, or analyses unless public health concerns unrecognized at the time of protocol assessment under this process are evident. Thus, documented special protocol assessments should be considered binding on the review division and should not be changed at any time..." as
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis ... (NYSE MKT: AMPE), today announced the presentation of ... Diagnostic System as a broadly applicable and robust ... in the body in response to injury, illness, ... performed in collaboration with Luoxis, academic and pharmaceutical ...
(Date:11/24/2014)... Nov. 24, 2014 The Female Health Company ... investor conference call to discuss its operating results for ... 2014 on Tuesday, December 2, 2014 at 11:00 a.m. ... its operating results earlier the same day. ... conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) ...
(Date:11/24/2014)... , Nov. 24, 2014  GlySens Incorporated announced ... million dollar grant from the National Institute of Diabetes ... the National Institutes of Health (NIH).  The grant is ... second generation ICGM™ long term implantable glucose monitoring system.  ... and enrollment is expected to begin before the end ...
Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... with Durezol Dosed Prior to Surgery, TAMPA, ... held ophthalmic-focused biopharmaceutical company, announced,today that Durezol(TM) (difluprednate ... was approved by the U.S. Food and,Drug Administration ... for the treatment of inflammation and pain associated ...
... MEETING, Pa., Oct. 6 Genaera,Corporation (Nasdaq: GENR ... trial of trodusquemine (MSI-1436), Genaera,s lead drug candidate,for the ... a novel,inhibitor of PTP1B, a validated molecular target that ... to normalize glucose and decrease,appetite. In the study, MSI-1436 ...
Cached Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4
(Date:11/24/2014)... November 24, 2014 Mental health ... day. They break up families, ruin careers, and ... hope for those that suffer,” says Hardy ... is showing that our specialized nutritional treatments can ... appear on “Mind Over Matter”, the premiere episode ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading national ... recognition in the 2015 Edition of U.S. News-Best Lawyers list ... unique combination of quality law practice and breadth of legal ... and especially grateful to our clients whose continued support of ... said Jeff S. Korek, senior partner at Gersowitz Libo ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... its patient care and billing like Tesco and Toyota to ... be improved by regularizing the movement of patients from Accident ... ,Services like redesigning, making improvements in healthcare, and giving ... Toyota group of companies, which needs to be copied by ...
... has stated, that it suspects that ‘Pneumonic plague’ is responsible ... according to preliminary test results// that it has conducted. The ... set up to treat patients. They also explained that the ... lack of security ,in the area. ,The outbreak ...
... of postgraduate students at Tshwane University of Technology (TUT) ... inch//. No, this is not revenge on your husband ... method to fight obesity. ,Department of sport ... Andrew McKune said that the group of 40 students ...
... resorted to the strike against OBC reservation in educational institutions, ... // to doctors for the strike period was not a ... no pay. If court orders to release the salaries, we ... to protests by medicos at the AIIMS for not getting ...
... Peace, Vijay Amritraj, has launched a charity that will ... ,The UN estimates that about 5.5 million ... a fraction is getting treatment despite the country's pharmaceutical ... ,Launching the `Amritraj Foundation' yesterday, the 53-year old sportsman, ...
... today said it has allotted 61,716 equity shares upon conversion ... FCCB holders. // ,The committee of directors at ... five each of the company at a premium of Rs ... each, the company informed the Bombay Stock Exchange., ,Consequently, ...
Cached Medicine News:
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
Microwell EIA for detection of Calcitonin...
Mircrowell EIA for detection of Intact PTH...
Medicine Products: